Search

Your search keyword '"Smit, E F"' showing total 27 results

Search Constraints

Start Over You searched for: Author "Smit, E F" Remove constraint Author: "Smit, E F" Publisher elsevier scientific publishers Remove constraint Publisher: elsevier scientific publishers
27 results on '"Smit, E F"'

Search Results

1. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.

2. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.

3. Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III study.

4. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.

5. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.

6. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.

7. The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer.

8. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).

9. Patterns of care and outcomes for stage IIIB non-small cell lung cancer in the TNM-7 era: Results from the Netherlands Cancer Registry.

10. Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET.

11. Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.

12. Costs of non-small cell lung cancer in the Netherlands.

13. Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC.

14. Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function.

15. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.

16. EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?

17. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.

18. SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer?

19. Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies.

20. Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions.

21. Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA.

22. Critical factors for patient management.

23. The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.

24. Fluorescence bronchoscopy for early detection of lung cancer: a clinical perspective.

25. Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling.

26. A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy.

27. Oral therapy for small cell lung cancer.

Catalog

Books, media, physical & digital resources